US equities |
INTC $66.19 ▼-28.10% AMZN $241.34 ▼-1.00% MU $891.06 ▼-4.63% NVDA $206.51 ▼-3.35% GOOGL $282.26 ▼-0.55% SNDK $1,190.83 ▼-10.47% SPCX $138.23 ▼-3.93% AMD $514.20 ▼-9.22%
FinancialContent

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.3113 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
US Stocks Fall; Tyson Foods Posts Upbeat Earnings ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite falling around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.08% to 34,254.53 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are worth checking out on Monday as we cover all of the biggest gainers and losers this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200’s Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100’s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Nasdaq Gains 50 Points; US Inflation Rate Rises In August ↗
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.11% to 34,685.47 while the NASDAQ... 
Via Benzinga
Topics Economy Stocks
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100’s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Microcap Firm ZyVersa Therapeutics Shows Promise Despite IPO Volatility, Analyst Initiates With Buy ↗
HC Wainwright initiated coverage on ZyVersa Therapeutics Inc (NASDAQ: ZVSA) with a Buy Rating and a  
Via Benzinga
Topics Initial Public Offering
News headline image
Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Biocept, Inc. (NASDAQ: BIOC) shares jumped 97.6% to $1.6608 after the company announced non-exclusive licensing agreement for CNSide with Plus Therapeutics. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results
From ZyVersa Therapeutics
Via GlobeNewswire
News headline image
Top 5 Health Care Stocks That Could Blast Off In August ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >